ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.2387C>T (p.Thr796Ile)

gnomAD frequency: 0.00005  dbSNP: rs80357364
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000047818 SCV000075831 likely benign Hereditary breast ovarian cancer syndrome 2024-01-28 criteria provided, single submitter clinical testing
GeneDx RCV000588791 SCV000210130 uncertain significance not provided 2014-08-15 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.2387C>T at the cDNA level, p.Thr796Ile (T796I) at the protein level, and results in the change of a Threonine to an Isoleucine (ACA>ATA). This variant, also known as 2506C>T using alternate nomenclature, has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA1 Thr796Ile was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Threonine and Isoleucine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA1 Thr796Ile occurs at a position that is moderately conserved across species and is not located in a known functional domain. In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available information, it is unclear whether BRCA1 Thr796Ile is pathogenic or benign. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000167276 SCV000218119 uncertain significance Hereditary cancer-predisposing syndrome 2021-02-18 criteria provided, single submitter clinical testing The p.T796I variant (also known as c.2387C>T), located in coding exon 9 of the BRCA1 gene, results from a C to T substitution at nucleotide position 2387. The threonine at codon 796 is replaced by isoleucine, an amino acid with similar properties. This alteration has been reported in multiple breast and/or ovarian cancer patients (Chao A et al. Oncotarget, 2016 Dec;7:85529-85541; Zhong X et al. PLoS One, 2016 Jun;11:e0156789; Li G et al. J. Cancer Res. Clin. Oncol., 2017 Oct;143:2011-2024; Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University RCV000240714 SCV000265884 uncertain significance Breast neoplasm 2015-11-01 criteria provided, single submitter research
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000588791 SCV000600285 likely benign not provided 2023-08-31 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000167276 SCV000683030 uncertain significance Hereditary cancer-predisposing syndrome 2022-10-17 criteria provided, single submitter clinical testing This missense variant replaces threonine with isoleucine at codon 796 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer (PMID: 27257965, 28664449, 30093976, 30982232) and ovarian cancer (PMID: 27907908, 32068069). However, this variant has also been detected in a breast cancer case-control meta-analysis in 7/60463 cases and 6/53461 unaffected individuals with a calculated OR=1.032 (95%CI 0.347 to 3.07) and Fisher's Exact test p-value=1 (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_000198). This variant has been identified in 12/250512 chromosomes (12/18394 East Asian chromosomes) in the general population by the Genome Aggregation Database (gnomAD). The available evidence is not sufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001778691 SCV000698945 uncertain significance not specified 2021-10-21 criteria provided, single submitter clinical testing Variant summary: BRCA1 c.2387C>T (p.Thr796Ile) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 250512 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in BRCA1 causing Hereditary Breast And Ovarian Cancer Syndrome (4.8e-05 vs 0.001), allowing no conclusion about variant significance. c.2387C>T has been reported in the literature in individuals affected with Breast or Ovarian Cancer (e.g. Chao_2016, Zhong_2016, Li_2017, Chan_2018, Wang_2019, Kwong_2020, Dorling_2021) but it was also reported in unaffected controls (Dong_2021, Dorling_2021). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
University of Washington Department of Laboratory Medicine, University of Washington RCV000167276 SCV003847712 likely benign Hereditary cancer-predisposing syndrome 2023-03-23 criteria provided, single submitter curation Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).
Breast Cancer Information Core (BIC) (BRCA1) RCV000111839 SCV000144399 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 1 2002-05-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.